Bedaquiline: Current Status and Future Perspectives

Bedaquiline: Current Status and Future Perspectives Publisher Pubmed

Khoshnood S¹ ; Goudarzi M² ; Taki E³ ; Darbandi A⁴ ; Kouhsari E⁵ ; Heidary M^{6, 7} ; Motahar M⁸ ; Moradi M⁸ ; Bazyar H⁹

Source: Journal of Global Antimicrobial Resistance Published:2021

Abstract

The development of drug-resistant tuberculosis (TB) is a major threat worldwide. Based on World Health Organization (WHO) reports, it is estimated that more than 500 000 new cases of drug-resistant TB occur annually. In addition, there are alarming reports of increasing multidrug-resistant TB (MDR-TB) and the emergence of extensively drug-resistant TB (XDR-TB) from different countries of the world. Therefore, new options for TB therapy are required. Bedaquiline (BDQ), a novel anti-TB drug, has significant minimum inhibitory concentrations (MICs) both against drug-susceptible and drug-resistant TB. Moreover, BDQ was recently approved for therapy of MDR-TB. The current narrative review summarises the available data on BDQ resistance, describes its antimicrobial properties, and provides new perspectives on clinical use of this novel anti-TB agent. © 2021 The Author(s)

Related Docs

View other Related Docs

1. Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium Tuberculosis, Frontiers in Microbiology (2021)

2. New Insights in to the Intrinsic and Acquired Drug Resistance Mechanisms in Mycobacteria, Frontiers in Microbiology (2017)

3. Molecular Detection of Rifampin, Isoniazid, and Ofloxacin Resistance in Iranian Isolates of Mycobacterium Tuberculosis by High-Resolution Melting Analysis, Infection and Drug Resistance (2018)

Experts (# of related papers)

View all Related Experts

Mohammad Mehdi Feizabadi (7)

Mehdi Yaseri (3)

Style	Citing Format
MLA	Khoshnood S, et al.. "Bedaquiline: Current Status and Future Perspectives." Journal of Global Antimicrobial Resistance, vol. 25, no. , 2021, pp. 48-59.
APA	Khoshnood S, Goudarzi M, Taki E, Darbandi A, Kouhsari E, Heidary M, Motahar M, Moradi M, Bazyar H (2021). Bedaquiline: Current Status and Future Perspectives. Journal of Global Antimicrobial Resistance, 25(), 48-59.
Chicago	Khoshnood S, Goudarzi M, Taki E, Darbandi A, Kouhsari E, Heidary M, Motahar M, Moradi M, Bazyar H. "Bedaquiline: Current Status and Future Perspectives." Journal of Global Antimicrobial Resistance 25, no. (2021): 48-59.
Harvard	Khoshnood S et al. (2021) 'Bedaquiline: Current Status and Future Perspectives', Journal of Global Antimicrobial Resistance, 25(), pp. 48-59.
Vancouver	Khoshnood S, Goudarzi M, Taki E, Darbandi A, Kouhsari E, Heidary M, et al.. Bedaquiline: Current Status and Future Perspectives. Journal of Global Antimicrobial Resistance. 2021;25():48-59.
BibTex	@article{ author = {Khoshnood S and Goudarzi M and Taki E and Darbandi A and Kouhsari E and Heidary M and Motahar M and Moradi M and Bazyar H}, title = {Bedaquiline: Current Status and Future Perspectives}, journal = {Journal of Global Antimicrobial Resistance}, volume = {25}, number = {}, pages = {48-59}, year = {2021} }
RIS	TY - JOUR AU - Khoshnood S AU - Goudarzi M AU - Taki E AU - Darbandi A AU - Kouhsari E AU - Heidary M AU - Motahar M AU - Moradi M AU - Bazyar H TI - Bedaquiline: Current Status and Future Perspectives JO - Journal of Global Antimicrobial Resistance VL - 25 IS - SP - 48 EP - 59 PY - 2021 ER -

Science Communicator Platform

Authors

Abstract